16 April 2024

dorsaVi enters aged care market with proprietary 'natural movement' AI algorithm

Key highlights:

- **dorsaVi has completed a major upgrade to its sensor technology with the development of an AI Natural Movement Algorithm (AI NMA), validated against gold-standard measures**
- **The AI NMA captures unique monitoring data via a single sensor and identifies when movements are outside normal levels**
- **The AI NMA expands addressable markets by providing GPs, and other users, early and predictive biomechanic monitoring especially suited for aged care facilities and with additional potential applications in post-spinal surgery patient analysis and quality assurance**
- **The AI NMA has been integrated into dorsaVi's existing solution, with commercial discussions currently underway across key global markets**

Melbourne, Australia, 16 April 2024: dorsaVi (ASX:DVL) (**dorsaVi** or the **Company**), developer of FDA approved wearable sensors and leader in human movement analytics, is pleased to announce the successful implementation of its AI Natural Movement Algorithm (AI NMA) to the Company's current sensor and product portfolio.

This advancement represents a significant milestone for the Company and builds upon the initial beta testing undergone from October 2022[1]. The AI NMA was developed using over 1000 hours of client training data, with a single dorsaVi sensor attached to the Upper Thoracic Spine. In addition, the AI NMA has been validated against Vicon's gold standard of movement analysis, further cementing dorsaVi as a global leader in the field of human movement analytics. This development allows dorsaVi to enter a range of markets with an initial focus in the aged care sector.

AI Natural Movement Algorithm

dorsaVi's AI NMA is embedded onto a single sensor and offers users a simple and effective method of assessing and monitoring progress in-and-out of the clinical environment. The AI NMA is able to capture subtle and unique data sets, as it allows the monitoring of subjects / patients in natural environments, such as at home, in a non-intrusive style via the single sensor placed at the upper part of the thoracic spine.

The AI NMA provides data on rehabilitation progress, biomechanical efficiencies and creates more personalised insights by gaining access to data that was previously inaccessible within the clinical setting. Clinical and physical therapists will now be able to assess how people move at home, the quality of their movement patterns, the number of movements, and gain insights on the quality of sleep. Additionally, the integration with AI allows clinicians to better understand risks in certain biomechanical movements.

[1] See ASX release 24 October 2022

The AI NMA is capable of predictively identifying and alerting how specific movements and activities can increase the risk of re-injury, biomechanical degradation, impede physiotherapy progress, add pressure to certain joints or pre-dispose users to clinically relevant events. This new set of innovative capabilities allows dorsaVi to identify and predict movements which may cause harm or biomechanical failure before it happens. The AI NMA offers customers a superior value proposition by enhancing the user experience and providing more unique assessments from a single device.

AI NMA in the Aged Care Sector

As the global population ages, the demand for advanced, non-intrusive monitoring solutions in the aged care sector is rapidly expanding. The AI NMA's innovative technology meets this growing need by enabling continuous, precise monitoring and early detection of movement-related abnormalities in elderly patients. This capability not only has the potential to improve patient outcomes by facilitating timely medical interventions but also positions dorsaVi to tap into a significant market opportunity, with potential expansion into other healthcare segments. This strategic focus on enhancing aged care with AI-driven solutions highlights dorsaVi's commitment to innovation and its potential for growth in the healthcare technology market.

dorsaVi's latest product offering aims to transform the aged care industry by addressing growing customer needs for in-home, non-intrusive monitoring. Additionally, the continual training data input allows the AI NMA to increase its predictive accuracy over time and anticipate movements which may lead to adverse clinical outcomes before they occur. The aged care market is the first commercial entry for the AI NMA however use cases for the product remain dynamic.

Movement disorders are highly prevalent within the aging population and ideal clinical management would involve 'round the clock' monitoring. AI NMA acts as a monitoring tool and provides actionable insights and potential precursors to adverse events such as falls, balance disturbances, and diminished daily activity levels. By promptly alerting concerned parties to such indicators, DVL can now facilitate timely intervention and preventive measures, thereby optimising patient safety and well-being within the aged care market and helping reduce healthcare costs.

The dynamic nature of the AI NMA allows clinicians (e.g. physiotherapists, GPs, and health care workers) to obtain subtle and sensitive outcome measures to assist with the monitoring and treatment of conditions with recognised movement-related signs such as Parkinson's Disease, multiple sclerosis, epilepsy, orthopedic conditions and others. Key biometric data now trackable includes: number of missteps, amount of sway while walking, poor ergonomics, biomechanical stability, joint pressure and overall quality of movement.

Currently, dorsaVi is in early discussions with major healthcare providers in the USA to begin implementing the Company's sensors with AI NMA into their existing product portfolio. dorsaVi aims to generate greater recurring revenues from its AI NMA and drive new sales growth within the aged care markets. The Company remains committed to refining its product offering based on feedback from clients and is focused on improving patient outcomes.

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, commented:

"I am delighted to announce the release of our Natural Movement Algorithm which will drive new commercial applications within the aged care sector domestically and internationally. This upgrade is the result of extensive clinical research, and we are proud of our technical team for creating such a unique solution with significant benefits. We look forward to advancing our relationships with current partners as we enter a new phase of potential growth in the global market".

The release of this announcement was authorised by the Board of dorsaVi.

– ENDS –

For further information about dorsaVi, please contact:

dorsaVi	**Investors**
Andrew Ronchi	Joel Seah
Chief Executive Officer	Vesparum Capital
+61 417 882 267	+61 3 8582 4800
ar@dorsavi.com	dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.

- **Clinical**: dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com